rss
J Neurol Neurosurg Psychiatry 2005;76:1611-1613 doi:10.1136/jnnp.2005.076315
  • Alzheimer's disease
  • Editorial commentary

Lipid lowering agents to delay cognitive decline in Alzheimer’s disease?

  1. F-E de Leeuw
  1. Correspondence to:
 Dr F-E de Leeuw
 Department of Neurology (HP326), University Medical Centre St Radboud, PO Box 9101, 6500HB Nijmegen, Netherlands; h.deleeuwneuro.umcn.nl

    More work to be done before concluding that lipid lowering agents are useful in Alzheimer’s disease

    There is conflicting evidence for a causal relation between cholesterol, its treatment, and the incidence of Alzheimer’s disease.1,2 Merely the finding of a reduced incidence of Alzheimer’s disease among statin users does not necessarily imply any beneficial clinical effect of cholesterol lowering in patients with Alzheimer’s disease.

    This gap in our understanding of the interplay between cholesterol and Alzheimer’s disease prompted Masse and colleagues3 to carry out the study on which they report in this months’ issue of the journal (see p 1624 of this issue).

    Previous reports on the effect of statins on the incidence of Alzheimer’s disease have always been criticised for possible weaknesses in …

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    BMJ Careers - Latest neurology and neurosurgery jobs